6X4T image
Deposition Date 2020-05-23
Release Date 2020-10-14
Last Version Date 2024-10-09
Entry Detail
PDB ID:
6X4T
Keywords:
Title:
Crystal structure of ICOS-L in complex with Prezalumab and VNAR domain
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
3.15 Å
R-Value Free:
0.25
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:ICOS ligand
Gene (Uniprot):ICOSLG
Chain IDs:A, C
Chain Length:240
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Prezalumab Fab Heavy chain
Chain IDs:B, D
Chain Length:224
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Prezalumab Fab Light chain
Chain IDs:E, F
Chain Length:214
Number of Molecules:2
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:VNAR
Chain IDs:G, H (auth: N)
Chain Length:130
Number of Molecules:2
Biological Source:Orectolobus maculatus
Primary Citation
Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies.
Nat Commun 11 5066 5066 (2020)
PMID: 33033255 DOI: 10.1038/s41467-020-18828-4

Abstact

The inducible co-stimulator (ICOS) is a member of the CD28/B7 superfamily, and delivers a positive co-stimulatory signal to activated T cells upon binding to its ligand (ICOS-L). Dysregulation of this pathway has been implicated in autoimmune diseases and cancer, and is currently under clinical investigation as an immune checkpoint blockade. Here, we describe the molecular interactions of the ICOS/ICOS-L immune complex at 3.3 Å resolution. A central FDPPPF motif and residues within the CC' loop of ICOS are responsible for the specificity of the interaction with ICOS-L, with a distinct receptor binding orientation in comparison to other family members. Furthermore, our structure and binding data reveal that the ICOS N110 N-linked glycan participates in ICOS-L binding. In addition, we report crystal structures of ICOS and ICOS-L in complex with monoclonal antibodies under clinical evaluation in immunotherapy. Strikingly, antibody paratopes closely mimic receptor-ligand binding core interactions, in addition to contacting peripheral residues to confer high binding affinities. Our results uncover key molecular interactions of an immune complex central to human adaptive immunity and have direct implications for the ongoing development of therapeutic interventions targeting immune checkpoint receptors.

Legend

Protein

Chemical

Disease

Primary Citation of related structures